Druck Icon

Eckert & Ziegler Expands in the European Prostate Cancer Market

Berlin, 25.06.2001. BEBIG Isotopen- und Medizintechnik GmbH, Berlin, a subsidiary of Eckert & Ziegler AG, which is listed on the Neuer Markt recently signed a contract valued at approximately 2 Mio EUR with Institut Curie, Paris. This contract will supply low radioactive implants, so-called seeds, for the normal tissue sparing treatment of prostate cancer. It is the largest contract to be awarded for this treatment in Europe. Institut Curie is one of the leading hospitals for radiotherapy against prostate cancer in France. Prostate cancer is the second most frequent cancer among men. In Europe 135.000 men are afflicted annually by this kind of cancer. Brachytherapy involves the precise placement of very small, low activity seeds into the prostate gland. This procedure can be performed on an outpatient basis, is less traumatic for the patient and has comparatively fewer side effects. Long term results of this therapy, which is already a well established treatment modality in the US, show that in most instances patients with localized prostate cancer have similar cure rates with fewer side effects than other modalities.

The Board of Directors